NASDAQ: EGRX - Eagle Pharmaceuticals, Inc.

半年間の収益性: -69.27%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Eagle Pharmaceuticals, Inc.


会社について Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

さらに詳しく
Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

IPO date 2014-02-12
ISIN US2697961082
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.eagleus.com
Цена ао 1.3
1日あたりの価格変動: 0% (1.3)
週ごとの価格変動: +52.94% (0.85)
月ごとの料金変更: +10.17% (1.18)
3ヶ月間の価格変動: +73.33% (0.75)
半年間の価格変動: -69.27% (4.23)
年間の価格変動: -78.15% (5.95)
3年間の価格推移: -97.49% (51.83)
5年間の価格推移: -97.53% (52.71)
10年間の価格推移: 0% (1.3)
年初からの価格変動: +160% (0.5)

過小評価

名前 意味 学年
P/S 1.2 9
P/BV 1.63 8
P/E 10.67 9
EV/EBITDA 5.92 9
合計: 9

効率

名前 意味 学年
ROA, % 10.8 4
ROE, % 17.39 5
合計: 4.5

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0.2257

義務

名前 意味 学年
Debt/EBITDA 0.9542 9
合計: 7.2

成長の衝動

名前 意味 学年
収益性 Revenue, % 48.43 6
収益性 Ebitda, % 91.84 9
収益性 EPS, % 30.52 5
合計: 4.4

ETF共有, %年間の利益率, %配当金, %
Royce Quant Small‑Cap Quality Value ETF 0.19827 21.83 1.62596
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.01366 17.58 1.75869
iShares Micro-Cap ETF 0.01037 17.09 1.54048
Schwab U.S. Small-Cap ETF 0.00121 17.47 1.51433
0.0618.491.61



スーパーバイザー 役職 支払い 生年
Mr. Michael Graves Interim Principal Executive Officer & Executive Chairman of the Board 160k 1963 (62 年)
Dr. Valentin R. Curt M.D. Senior Vice President of Clinical Drug Development N/A
Dr. Gaozhong Zhu Ph.D. Senior Vice President of Pharmaceutical Development N/A
Mr. Reed McClung Executive Vice President of Oncology Business Development N/A
Mr. Steven B. Ratoff Interim CFO, Principal Accounting Officer & Director 100k 1943 (82 年)
Mr. Daniel O'Connor Executive VP, Chief Strategy Officer & Head of Corporate Development 1980 (45 年)
Ms. Debra Marie Hussain Senior VP & Head of Commercial 1968 (57 年)

住所: United States, Woodcliff Lake. NJ, 50 Tice Boulevard - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.eagleus.com